Maintenance Therapy in HER2+ Metastatic Breast Cancer (MBC)
Pfizer External Research & Grants (ER&G) (formerly Global Medical Grants & Partnerships) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s ER&G competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
Date RFP Issued: Mar 4, 2026
Geographic Scope: United States
Clinical Area: Oncology-Breast Cancer
Link to full RFP: Maintenance Therapy in HER2+ Metastatic Breast Cancer (MBC)
Application Due Date: Apr 21, 2026
Specific Area of Interest: Independent education projects should improve knowledge and competence of:
· Combinations in the 1L HER2+ MBC maintenance setting
· Overall treatment paradigm and evolving first-line standard of care options for patients with HER2+ MBC
· Safety profiles of available therapies
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.